

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregory A. Demopulos et al. Attorney Docket No.: PH.1.0006.US2
Application No.: 10/674,290 Group Art Unit: 1614
Filed: September 29, 2003 Examiner: Brian Yong S. Kwon
Title: VASCULAR IRRIGATION SOLUTION AND METHOD FOR INHIBITION
OF PAIN, INFLAMMATION, SPASM AND RESTENOSIS

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

September 23, 2004

TO THE COMMISSIONER FOR PATENTS:

A. Transmitted herewith are the following:

- X 1. Information Disclosure Statement
- X 3. Citation of Information
- X 3. Small entity status is asserted for this matter.

COMPUTATION OF FEES

	Number Filed	Number Extra	Rate		
Basic Fee					
Total Claims	=	x	9.00	=	0.00
Independent Claims	=	x	42.00	=	0.00
Multiple Dependent Claim		+			
Surcharge		+			
Extension of Time		+			
TOTAL					\$0.00

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

B. Fees Enclosed

☒ No fees are required at this time.

C. Additional Fee Charges or Credit for Overpayment

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 502230. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

OMEROS CORPORATION




Marcia S. Kelbon
VP, Patent & General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:


9/23/04



Stephanie Jansen

MSK/sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory A. Demopoulos et al. Attorney Docket No.: PH.1.0006.US2
Application No.: 10/674,290 Group Art Unit: 1614
Filed: September 29, 2003 Examiner: Brian Yong S. Kwon
Title: VASCULAR IRRIGATION SOLUTION AND METHOD FOR INHIBITION
OF PAIN, INFLAMMATION, SPASM AND RESTENOSIS

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

September 23, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. a. X This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/195,625, filed July 12, 2002, issued as U.S. Patent No. 6,645,168, and is a continuation of U.S. Application No. 09/837,141, filed April 17, 2001, issued as U.S. Patent No. 6,420,432, which is a continuation of U.S. Application No. 09/072,913, filed May 4, 1998, issued as U.S. Patent No. 6,261,279, which is a continuation of U.S. Application No. 08/670,699, filed June 26, 1996, issued as U.S. Patent No. 5,820,583, which is a continuation-in-part of International Application No. PCT/US95/16028, filed December 12, 1995, designating the United States, which is a continuation-in-part of U.S. Application No. 08/353,775, filed December 12, 1994, now abandoned, priority from the filing dates of which is hereby claimed under 35 U.S.C. § 120.
- b. X The references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in the priority applications and, therefore, are not required to be provided in this application. However, if the Examiner would find it convenient to receive duplicate copies of any of these references, the Examiner is requested to telephone the undersigned attorney.
- c. X Applicants also wish to make known to the U.S. Patent Office the following U.S. Applications that describe and claim subject matter that is similar to the subject matter of this application and rely on the earlier filing dates of the same priority

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

applications identified above. These related applications, as well as any prior art cited therein, may be material to the examination of this application.

U.S. Applications(s):


Application No.	Filing Date	Status
09/839,633	04/20/2001	Pending
10/138,192	05/01/2002	Pending
10/138,193	05/01/2002	Pending
10/180,815	06/25/2002	Pending
10/288,997	11/06/2002	Pending
10/760,639	01/20/2004	Pending
10/760,708	01/20/2004	Pending
10/820,217	04/02/2004	Pending
10/878,973	06/28/2004	Pending
10/915,962	08/11/2004	Pending

2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 502230. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

Respectfully submitted,

OMEROS CORPORATION



Marcia S. Kelbon
VP, Patent & General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

9/23/04
Date

SM
Stephanie Jansen

MSK:sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688



**INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL
TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: G.A. Demopoulos et al. Attorney Docket No: PH.1.0006.US2
Serial No: 10/674,290 Group Art Unit: 1614
Filed: September 29, 2003 Examiner: Brian Yong S. Kwon
Title: VASCULAR IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF
PAIN, INFLAMMATION, SPASM AND RESTENOSIS

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Name
_____	U1	4,504,493	03/12/1985	Marshall et al.
_____	U5	5,051,443	09/24/1991	Neufeld et al.
_____	U6	5,272,139	12/21/1993	Cary
_____	U11	4,872,865	10/10/1989	Bloebaum et al.
_____	U14	4,938,970	07/1990	Hustead et al.
_____	U16	5,304,724	04/19/1999	Newton, W.
_____	U19	5,411,743	05/02/1995	Moore et al.
_____	U24	5,288,725	02/22/1994	Witherup et al.
_____	U25	4,640,912	02/03/1987	Hausman, M.
_____	U27	5,525,357	06/11/1996	Keefer et al.
_____	U28	5,536,241	07/16/1996	Zapol, W.
_____	U29	5,512,055	04/30/1996	Domb et al.
_____	U30	5,019,601	05/28/1991	Allen, Deceased
_____	U36	5,482,925	01/09/1996	Hutsell
_____	U37	5,370,614	12/06/1994	Amundson et al.
_____	U38	5,336,178	08/09/1994	Kaplan et al.
_____	U39	5,620,687	04/15/1997	Hart et al.
_____	U45	4,525,359	06/25/1985	Greenway, III et al.
_____	U56	4,880,791	11/14/1989	Weithmann et al.
_____	U62	5,618,563	04/08/1997	Berde et al.
_____	U63	5,658,955	08/19/1997	Hitzig

_____	U70	5,744,482	04/28/1998	Cohen et al.
_____	U79	4,659,714	04/21/1987	Watt-Smith
_____	U164	5,800,385	09/01/1998	Demopulos et al.
_____	U165	5,820,583	10/13/1998	Demopulos et al.
_____	U183	5,994,372	11/30/1999	Yaksh
_____	U209	5,942,241	8/24/1999	Chasin et al.
_____	U213	5,767,105	06/16/1998	Peyman
_____	U272	5,858,017	01/12/1999	Demopulos et al.
_____	U273	5,860,950	01/19/1999	Demopulos et al.
_____	U274	6,210,394	04/03/2001	Demopulos et al.
_____	U275	6,242,447 B1	06/05/2001	Demopulos et al.
_____	U276	6,254,585 B1	07/03/2001	Demopulos et al.
_____	U277	6,261,279 B1	07/17/2001	Demopulos et al.
_____	U278	6,056,715	05/02/2000	Demopulos et al.
_____	U279	5,446,070	8/29/1995	Mantelle
_____	U280	5,610,184	3/11/1997	Shahinian, Jr.
_____	U281	5,667,764	9/16/1997	Kopia et al.
_____	U282	5,480,901	1/2/1996	Baker et al.
_____	U284	6,306,820 B1	10/23/2001	Bendele et al.
_____	U285	5,180,812	1/19/1993	Dower et al.
_____	U425	5,523,316	06/24/1996	Gan et al.
_____	U491	6,413,961	07/02/2002	Demopulos et al.
_____	U492	6,420,432	07/16/2002	Demopulos et al.
_____	U553	5,624,893	04/29/1997	Yanni
_____	U646	6,645,168	11/11/2003	Demopulos et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Publication Date	Country	Translation Provided	
					Yes	No
_____	F1	WO 95/16435	06/22/1995	PCT	X	
_____	F2	EP 0,364,266 A2	04/18/1990	European	X	
_____	F7	WO 92/04008	03/19/1992	PCT	X	
_____	F8	EP 0,351,755	01/24/1990	European	X	
_____	F9	WO 95/27482	10/19/1995	PCT	X	
_____	F10	WO 91/04058	04/04/1991	PCT	X	
_____	F16	WO 96/29074	09/26/1996	European	X	
_____	F29	WO 96/26738	09/06/1996	European	X	
_____	F83	EP 0,715,855 A2	06/12/1996	European	X	
_____	F84	EP 0,710,479 B1	01/07/1999	European	X	

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O01	Thulesius, O., et al., "Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications," <i>J. Cardiovasc. Pharmacol.</i> 9 :728-733 (1987).
_____	O02	Hedner, T., et al., "Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension," <i>Am. J. Hypertens.</i> 1 :317S-323S (1988).
_____	O03	Hof, R.P., et al., "Antiarrhythmic and hemodynamic effects of tropisetron in anesthetized rabbits," <i>J. Cardiovasc. Pharmacol.</i> 22 :499-505 (1993).
_____	O05	Naesh, O., et al., "Platelet activation in mental stress," <i>Clin. Physiol.</i> 13 :299-307 (1993).
_____	O06	Evans, R.G., et al., "Effects of 5-HT-receptor and alpha 2-androceptor ligands on the haemodynamic response to acute central hypovolemia in conscious rabbits," <i>Br. J. Pharmacol.</i> 109 :37-47 (1993).

- _____ O07 Van Hemelrijck, J., et al., "Blood pressure management during aortic surgery: urapidil compared to isosorbide dinitrate," *J. Cardiothorac. Vasc. Anesth.* **7**:273-278 (1993).
- _____ O08 Evans, R.G., et al., "A CNS serotonergic mechanism in acute central hypovolemia in conscious rabbits?" *J. Cardiovasc. Pharmacol.* **19**:1009-1017 (1992).
- _____ O10 Vyssoulis, G.P., et al., "Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives," *Cardiovasc. Drugs Ther.* **4**:81-84 (1990).
- _____ O11 Sigal, S.L., et al., "Effects of Serotonin-Receptor Blockade on Angioplasty-Induced Vasospasm in an Atherosclerotic Rabbit Model," *Arterioscler. Thrombosis* **11**:770-783 (1991).
- _____ O12 Kalsner, S., et al., "Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm," *Science* **223**:1435-1437 (1984).
- _____ O13 Willerson, J.T., et al., "Specific Platelet mediators and unstable coronary artery lesions," *Circulation* **80**:198-205 (1989).
- _____ O14 Saxena, P.R., et al., "Cardiovascular effects on serotonin agonists and antagonists," *J. Cardiovasc. Pharmacol.* **15**:S17-S34 (1990).
- _____ O16 Ashton, J.H., et al., "Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries," *Circulation* **73**:572-578 (1986).
- _____ O20 Kessler, W., et al., "Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P," *Exp. Brain Res.* **91**:467-476 (1992).
- _____ O23 Levine, J.D., et al., "Desipramine enhances opiate postoperative analgesia," *Pain* **27**:45-49 (1986).
- _____ O26 Ringkamp, M., et al., "Activated human platelets in plasma excite nociceptors in rat skin, in vitro," *Neurosci. Lett.* **170**:103-106 (1994).
- _____ O32 Buzzi, M.G., et al., "The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater," *Br. J. Pharmacol.* **99**:202-206 (1990).

- _____ O33 Buzzi, M.G., et al., "5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation," *Brain Res.* **583**:137-149 (1992).
- _____ O34 Zochodne, D.W., et al., "Sumatriptan blocks neurogenic inflammation in the peripheral nerve trunk," *Neurology* **44**:161-163 (1994).
- _____ O37 Schwartz, M.M., et al., "Vascular leakage in the kidney and lower urinary tract: effects of histamine, serotonin and bradykinin," *Proc. Soc. Exp. Biol. Med.* **140**:535-539 (1972).
- _____ O38 Holliman, C.J., et al., "The effect of ketanserin, a specific serotonin antagonist, on burn shock hemodynamic parameters in a porcine burn model," *J. Trauma* **23**:867-871 (1983).
- _____ O39 Serruys, P.W., et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty; a multicenter randomized double-blind placebo-controlled trial," *Circulation* **88**:1588-1601 (1993).
- _____ O40 Cohen, B.M., et al., "Intracoronary cocktail infusion during rotational ablation: safety and efficacy," *Transcatheter Cardiovascular Therapeutics* (1995).
- _____ O42 Araki, H., et al., "Longitudinal Propagation of Contraction in the Isolated Conduit Coronary Arteries of Humans and Pigs," *Circulation Research* **64**(4):734-741 (1989).
- _____ O43 Berkenboom, G., et al., "Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators," *J. Cardiovasc. Pharmacol.* **14**:S35-S39 (1989).
- _____ O44 Kaumann, A.J., et al., "Variable participation of 2HT1-like receptors and 5-HT1 receptors in serotonin-induced contraction of human isolated coronary arteries," *Circulation* **90**:1141-1153 (1994).
- _____ O45 Quast, U., et al., "Cellular Pharmacology of Potassium Channel Openers in Vascular Smooth Muscle," *Cardiovascular Research* **28**:805-810 (1994).
- _____ O61 Liu, J.J., et al., "Synergistic Effect of Nisoldipine and Nitroglycerin on Human Internal Mammary Artery," *J. Pharmacol. Exp. Therapeutics* **268**(1):434-440 (1994).

- _____ O62 Cohen, D.J., et al., "Intraoperative coronary artery spasm successfully treated with nitroglycerin and nifedipine," *Annals of Thor Surg* **36**:97-100 (1983).
- _____ O86 Golino, P., et al., "Failure of nitroglycerine and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A₂ and serotonin as mediators of coronary artery vasoconstriction in vivo," *J. Am. Coll. Cardiol.* **15**:718-726 (1990).
- _____ O89 DeCaterina, R., et al., "A Double-blind, Placebo-controlled Study of Ketanserin in Patients with Prinzmetal's Angina," *Circulation* **69**:889-894 (1984).
- _____ O90 Golino, P., et al., "Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Artherosclerosis and Control Patients," *New Engl. J. Med.* **324**:641-648 (1991).
- _____ O91 Golino, P., et al., "Local Effect of Serotonin Released During Coronary Angioplasty," *New Engl. J. Med.* **330**:523-528 (1994).
- _____ O92 Golino, P., et al., "Endogenous prostaglandin endoperoxides and prostacyclin modulate and thrombolytic activity of tissue plasminogen activator," *J. Clin. Invest.* **86**:1095-1102 (1990).
- _____ O93 Ashton, J.H., et al., "Serotonin S₂ and Thromboxane A₂-Prostaglandin H₂ Receptor Blockade Provide Protection Against Epinephrine-Induced Cyclic Flow Variations in Severly Narrowed Canine Coronary Arteries," *J. Am. Coll. Cardiol.* **13**:755-763 (1989).
- _____ O94 Yao, S., et al., "Combined ADP and Thromboxane A₂ Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium-Injured Arteries in Nonhuman Primates," *Circulation* **88**:2888-2893 (1993).
- _____ O95 Yao, S., et al., "Combination of inhibition of thrombosis and blockade of Thromboxane A₂ synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries," *Circulation* **86**:1993-1999 (1992).
- _____ O104 Willerson, J.T., et al., "Liposome-Bound Prostaglandin E₁ Often Prevents Cyclic Flow Variations in Stenosed and Endothelium-Injured Canine Coronary Arteries," *Circul. Res.* **89**(4):1786-1791 (1994).

- _____ O114 Podesser, B., et al., "Combined perioperative infusion of nifedipine and metoprolol provides antiischemic and antiarrhythmic protection in patients undergoing elective aortocoronary bypass surgery," *Thorac Cardiovasc Surgeon* **41**:173-179 (1993).
- _____ O115 Hannes, W., et al., "Effect of Peri-Operative Diltiazem on Myocardial Ischaemia and Function in Patients Receiving Mammary Artery Grafts," *Europ Heart J* **16**(1):87-93 (1995).
- _____ O116 Cohen, B.M., et al., "Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot," *Cathet. Cardiovasc. Diagn. Suppl.* **3**:69-72 (1996).
- _____ O117 Yao, S.K., et al., "Combined Thrombin Inhibition and Thromboxane A₂ Synthesis and Receptor Blockade Enhances Thrombolysis and Delays Arterial Reocclusion," *Suppl to Journal of the American College of Cardiology, Abstracts 41st Annual Scientific Session* **19**(3):329A (1992).
- _____ O129 Reuben, S.S., et al., "Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular bupivacaine and ketorolac," *Anesth. Analg.* **80**:1154-1157 (1995).
- _____ O133 Sosnowski, M., et al., "Spinal Administration of Receptor-Selective Drugs as Analgesics: New Horizons," *J. Pain Symptom Manag.* **5**:204-213 (1990).
- _____ O149 Gyrn, J., et al., "Intra-articular Bupivacaine Plus Adrenoline for Arthroscopic Surgery of the Knee," *Acta Anaesthesiol. Scand.* **36**:643-646 (1992).
- _____ O157 Thomas, et al., "The Direct Perfusion of Surgical Wounds with Local Anaesthetic Solution: An Approach to Postoperative Pain?" *Annal R Coll Surg* **65**:226-229 (1983).
- _____ O160 Kuga, T., et al., "Inhibitory Effects of Aspirin on Coronary Hyperreactivity to Autacoids After Arterial Balloon Injury in Minature Pigs," *J. Cardiovasc. Pharmacol.* **25**:273-281 (1995).
- _____ O171 Golino, P., et al., "Inhibition of Neutrophil Adhesion Proteins Reduces Neointimal Hyperplasia Following Arterial Injury in Rabbit Carotid Arteries," *Am Heart Assoc, Abstracts 67th Scientific Sessions* **90**(4)(part 2):I-85 (1994).
- _____ O175 Reifart, et al., "Randomized Comparison of Angioplasty of Complex Coronary Lesions at a Single Center," *Circulation* **96**:91-98 (1997).

- _____ O176 Yao, S.K., et al., "Endogenously Produced EDRF Protects Against Platelet Aggregation and Cyclic Flow variations in Stenosed and Endothelium-Injured Arteries," *Suppl to Journal of the American College of Cardiology, Abstracts 41st Annual Scientific Session* **19(3):376A** (1992).
- _____ O177 Liu, M.W., et al., "Intraluminal Alcohol Delivery Reduced Intimal Hyperplasia after Ballon Injury in Pig Coronary Arteries. A Concept of Chemical Atherectomy," *Am Heart Assoc, Abstracts 66th Scientific Sessions* **88(4)(part 2):I-655** (1993).
- _____ O178 Willerson, J.T., et al., "Pretreatment with Antagonists to Thromboxane A₂, Serotonin and ADP Reduces Neointimal Proliferation in Canine Coronary Arteries after Endothelial Injury," *J. Am. Coll. Cardiol.* **Incomplete Data:906-32**(1994).
- _____ O179 Liu, M. et al., "A Preliminary Report of Local Alcohol Delivery for Treatment of Restensosi within Stented Segments After Successful Caoronary Angioplasty. The Safety Study of Local Alcohol and Stent Against Restensosis (LASAR) Trial." *Joournal of the American College of Cardiology, Abstracts 45th Annual Scientific Session* **112A** (1996).
- _____ O180 Knorr, A.M. "Why is Nisoldipine a Specific Agent in Ischemic Left Ventricular Dysfunction?" *Am. J. Cardiol.* **75:36E-40E** (1995).
- _____ O181 Pierce, P.A., et al., "Dual Effect of the Serotonin Agonist, Sumatriptan, on Peripheral Neurogenic Inflammation," *Reg. Anesth.* **21:219-225** (1996).
- _____ O183 Herrman et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty," *Drugs* **46:18-52** (1993).
- _____ O184 Vahanian et al., "Role of Calcium Channel Blockers in Reducing Acute Ischemia and Preventing Restenosis in PCTA," *Drugs* **52:9-15** (1996).
- _____ O185 Narayanan et al., "Recombinant Hirudin: Initial Observations in Reconstructive Microsurgery," *Haemostasis* **21:168-171** (1991).
- _____ O186 el-Sanadiki, M.N., et al., "Reduction of Intimal Hyperplasia and Enhanced Reactivity of Experimental Vein Bypass Grafts with Verapamil Treatment," *Ann. Surg.* **212:87-96** (1990).
- _____ O187 Gibbons, G.H., et al., "Molecular Therapies for Vascular Diseases," *Science* **272:689-693** (1996).

- O188 Jackson, C.L., et al., "Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size," *Atherosclerosis* **69**:115-122 (1988).
- O189 Jackson, C.L., et al., "Mechanism of antiatherogenic action of calcium antagonists," *Atherosclerosis* **80**:17-26 (1989).
- O190 Lefkovits, J., et al., "Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention," *Prog. Cardiovasc. Dis.* **40**(2):141-158 (1997) (Abstract only).
- O191 Lloyd-Jones, D.M., et al., "The Vascular Biology of Nitric Oxide and its Role in Atherogenesis," *Annual Rev. Med.* **47**:365-75 (1996).
- O192 Nomoto, A., et al., "Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist," *Atherosclerosis* **64**:255-261 (1987).
- O194 Wheeler, D.B., et al., "Neuronal calcium channels encoded by the α_{1A} subunit and their contribution to excitatory synaptic transmission in the CNS," *Progress in Brain Research* **105**:65-78 (1995).
- O196 Hirayama et al., "NK₁ Receptors Mediate Tachykinin-Induced Plasma Extravasation in the Rat Knee," *Agents Actions* **40**:171-175 (1994).
- O215 Khoury, G., et al., "Intraarticular morphine, bupivacaine, and morphine/bupivacaine for pain control after knee videoarthroscopy," *Anesthesiology* **77**:263-266 (1992).
- O219 Allen, G., et al., "Postarthroscopy analgesia with intraarticular bupivacaine/morphine. A randomized clinical trial," *Anesthesiology* **79**:475-480 (1993).
- O234 Bisla, K., et al., "Concentration-dependent effects of lidocaine on corneal epithelial wound healing," *Invest Ophthalmol. Vis. Sci.* **33**:3029-3033 (1992).
- O238 Massey, T., et al., "Serum lidocaine levels during arthroscopy using continuous irrigation with lidocaine," *Clin. Orthop.* **229**:182-184 (1988).
- O239 Tsai, L., et al., "Arthroscopic surgery of the knee in local anaesthesia. An analysis of age-related pathology," *Arch. Orthop. Trauma Surg.* **112**:136-138 (1993).

- _____ O242 Klein, J.A., "Tumescent Liposuction and Improved Postoperative Care Using Tumescent Liposuction Garments," *Dermatologic Clinics* **13**:329-338 (1995).
- _____ O244 Klein, J.A., "The Tumescent Technique Anesthesia and Modified Liposuction Technique," *Dermatologic Clinics* **8**:425-437 (1990).
- _____ O246 Ostad et al., "Tumescent Anesthesia with a Lidocaine Dose of 55 mg/kg is Safe for Liposuction" *Dermatol Surg* **22**:921-927 (1996).
- _____ O253 Wredmark, et al., "Arthroscopy Under Local Anaesthesia Using Controlled Pressure-Irrigation With Prilocaine," *J Bone Joint Surg* **64**:583-585 (1982).
- _____ O367 Talke, P., et al., "Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group," *Anesthesiology* **82**:620-633 (1995).
- _____ O842 Ben-David et al., "Is Preoperative Ketorolac A Useful Adjunct To Regional Anesthesia For Inguinal Herniorrhaphy?" *Acta Anaesthesiol Scand* **40**:358-363 (1996).
- _____ O843 Hyrkäs et al., "Effective Postoperative Pain Prevention Through Administration Of Bupivacaine And Diclofenac," *Anesth Prog* **41**:6-10 (1994).
- _____ O844 Glasser et al., "The Perioperative Use Of Corticosteroids And Bupivacaine In The Management Of Lumbar Disc Disease," *J Neurosurg* **78**: 383-387 (1993).
- _____ O845 Dionne et al., "Suppression Of Postoperative Pain By The Combination Of A Nonsteroidal Anti-Inflammatory Drug, Flurbiprofen, And A Long-Acting Local Anesthetic, Etidocaine," *JADA* **108**:598-601 (1984).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:sj